Longitudinal study of patients with anti-SAE antibody-positive dermatomyositis: a multicenter cohort study in China

被引:2
|
作者
Zhang, Yingfang [1 ,2 ]
Liu, Lei [3 ]
Duan, Xinwang [4 ]
Pi, Hui [5 ]
Jiang, Lili [5 ]
Li, Jiang [6 ]
Wang, Guochun [1 ,2 ,7 ,8 ]
Shu, Xiaoming [1 ,2 ,7 ,8 ]
机构
[1] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Dept Rheumatol, Key Lab Myositis, Beijing, Peoples R China
[3] Zhejiang Univ, Dept Rheumatol, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 2, Dept Rheumatol & Immunol, Nanchang, Jiangxi, Peoples R China
[5] Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Affiliated Hosp 1, Dept Rheumatol, Nanchang, Peoples R China
[6] China Japan Friendship Hosp, Dept Lab Med, Beijing, Peoples R China
[7] China Japan Friendship Hosp, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China
[8] China Japan Friendship Hosp, Dept Rheumatol, Yinghua East Rd, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
anti-SAE antibody; DM; skin rash; cancer; interstitial lung disease; outcome; MODIFIER ACTIVATING ENZYME; IDIOPATHIC INFLAMMATORY MYOPATHIES; MYOSITIS-SPECIFIC AUTOANTIBODIES; CLINICAL-SIGNIFICANCE; JAPANESE PATIENTS; CANCER; ADULT; CLASSIFICATION; IDENTIFICATION; POLYMYOSITIS;
D O I
10.1093/rheumatology/keae232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe the longitudinal study and long-term prognosis of a multicentre large inception cohort of patients with anti-SAE positive DM.Methods We retrospectively recruited patients with anti-SAE+DM in four tertiary referral centres from China between March 2005 and December 2022. Long-term survival analysis was performed on the enrolled patients. The Myositis Damage Index and Cutaneous Disease Area and Severity Index were used to evaluate the degree of different organ damage and the extent of skin rashes. Longitudinal CT patterns were analysed. Phenotypes were characterized using unsupervised cluster analysis.Results All-cause death occurred in 10.5% (4/38) of all patients, in which three patients succumbed to malignancies at 13, 18 and 36 months. Most patients had favourable long-term outcomes, 35.3% of them were in drug-free remission. Skin rashes showed significant improvement evaluated by Cutaneous Disease Area and Severity Index with time. However, damage to different systems was observed in 70.6% of the surviving patients using the Myositis Damage Index, which mainly consisted of skin damage, accounting for 47.1%. Nine patients with anti-SAE+DM-associated interstitial lung disease underwent repeat CT showed marked radiological improvement at 6 months or being stable after 12 months. In further, different characteristics and outcomes were also showed in three clusters identified by unsupervised analysis.Conclusions Anti-SAE+DM is characterized with a lower mortality rate and the development of malignancies being the primary cause of death. Patients who survived showed notable cutaneous damage, while the interstitial lung disease tends to stabilize. Clusters identified with unsupervised analysis could assist physicians in identifying a higher risk of mortality.
引用
收藏
页码:1377 / 1385
页数:9
相关论文
共 50 条
  • [21] Mortality risk in patients with anti-MDA5 antibody-positive dermatomyositis: A risk assessment
    Kawada, Tomoyuki
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 69
  • [22] Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review
    Ertao Jia
    Jiaxin Wei
    Hongling Geng
    Xia Qiu
    Jingjing Xie
    Yuya Xiao
    Li Zhong
    Min Xiao
    Yanying Zhang
    Yubao Jiang
    Jianyong Zhang
    Clinical Rheumatology, 2019, 38 : 2189 - 2193
  • [23] Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China
    Li, S.
    Gao, S.
    Chen, Q.
    Han, J.
    Zhang, L.
    Ge, Y.
    Zuo, Y.
    Duan, J.
    Lu, X.
    Wang, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (02) : 284 - 291
  • [24] Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis
    Nagashima, Takao
    Kamata, Yasuyuki
    Iwamoto, Masahiro
    Okazaki, Hitoaki
    Fukushima, Noriyoshi
    Minota, Seiji
    RHEUMATOLOGY INTERNATIONAL, 2019, 39 (05) : 901 - 909
  • [25] Evaluation of Prognostic Factors in Anti-MDA5 Antibody-Positive Patients in Chongqing, China: A Retrospective Study
    Zhou, Jun
    Huang, Wenhan
    Ren, Feifeng
    Luo, Lei
    Huang, Dongmei
    Tang, Lin
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 4775 - 4781
  • [26] Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report
    Takayuki Kishi
    Yumi Tani
    Naoko Okiyama
    Kiyoshi Mizuochi
    Yuki Ichimura
    Masayoshi Harigai
    Satoru Nagata
    Takako Miyamae
    Pediatric Rheumatology, 19
  • [27] Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review
    Jia, Ertao
    Wei, Jiaxin
    Geng, Hongling
    Qiu, Xia
    Xie, Jingjing
    Xiao, Yuya
    Zhong, Li
    Xiao, Min
    Zhang, Yanying
    Jiang, Yubao
    Zhang, Jianyong
    CLINICAL RHEUMATOLOGY, 2019, 38 (08) : 2189 - 2193
  • [28] Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies
    Muro, Yoshinao
    Ishikawa, Asuka
    Sugiura, Kazumitsu
    Akiyama, Masashi
    RHEUMATOLOGY, 2012, 51 (08) : 1508 - 1513
  • [29] Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum
    Yashiro, Makiko
    Asano, Tomoyuki
    Sato, Shuzo
    Kobayashi, Hiroko
    Watanabe, Hiroshi
    Miyata, Masayuki
    Migita, Kiyoshi
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2018, 64 (02) : 89 - 94
  • [30] Anti-aminoacyl tRNA synthetase antibody-positive clinically amyopathic dermatomyositis
    Ebisudani, T.
    Asakura, T.
    Ueda, S.
    Ishii, M.
    Betsuyaku, T.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2018, 111 (06) : 425 - 426